Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Daridorexant - Idorsia Pharmaceuticals

Drug Profile

Daridorexant - Idorsia Pharmaceuticals

Alternative Names: ACT-541468; DORA; Nemorexant - Idorsia Pharmaceuticals

Latest Information Update: 17 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Actelion Pharmaceuticals
  • Developer Idorsia Pharmaceuticals
  • Class Benzimidazoles; Chlorinated hydrocarbons; Ketones; Pyrrolidines; Sleep disorder therapies; Small molecules; Triazoles
  • Mechanism of Action Orexin receptor type 1 antagonists; Orexin receptor type 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Insomnia
  • Phase I Sleep apnoea syndrome

Most Recent Events

  • 23 Jul 2020 Idorsia Pharmaceuticals plans to submit a regulatory application to the US FDA for Insomnia by end of 2020
  • 07 Jul 2020 Efficacy and adverse events data from a second phase III trial in Insomnia released by Idorsia Pharmaceuticals
  • 26 May 2020 Idorsia Pharmaceuticals plans a phase I drug-drug interaction trial in volunteers in Germany (NCT04390334)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top